SEED and Eisai Partner on Groundbreaking Biotech Research

Beyondspring (BYSI) has released an update.

SEED Therapeutics has announced a strategic research collaboration with Eisai Co., Ltd. to develop molecular glue degraders targeting neurodegenerative diseases and cancer, with potential payments up to $1.5 billion plus royalties. Additionally, SEED has initiated a Series A-3 financing round, led by Eisai, raising $24 million to advance their cancer treatment programs and expand their Targeted Protein Degradation (TPD) platform. This move strengthens SEED’s position in developing treatments for diseases with limited options and showcases their growth in the biotech sector, bolstered by prior investments from Eli Lilly and BeyondSpring.

For further insights into BYSI stock, check out TipRanks’ Stock Analysis page.